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CLOSURE FOLLOW-UP CARE FOR THE UNDECIDED BONE MARROW
TRANSPLANT PATIENT
Calamusa, J.M.; Stary, S.; Goodie, M.; Maugans, W.; Adornetto, D.;
Burton, J. MD Anderson Cancer Center, Houston, TX
The Bone Marrow Transplant program at MD Anderson Can-
cer Center has four coordinators responsible for following the
patient from initial consultation to transplant admission. As the
patient’s journey from consult to transplant was reviewed, the
coordinator’s process of tracking the undecided patient was
reviewed. It was determined that an inconsistent tracking and
follow-up method was occurring, amongst the coordinator team.
Thus, a process improvement project evolved. In order to pro-
vide more efficient care for our patients within a complex sys-
tem, a new tracking system was implemented. The new tracking
system outlines the frequency method of follow-up for our
patients and concludes with a written letter. In the letter, we
provide any assistance in forwarding any information to the
physician of their choice. The patient is encouraged to have con-
tinued follow-up care. The patient is also encouraged to contact
the Bone Marrow Transplant coordinator at M.D. Anderson
with any questions or changes in decision /disease status. The
policy is designed to eliminate the possibility of the patient being
“lost” in our system. The focus of the policy is to provide effi-
cient, consistent care to the patient and also to document com-
munication. The policy creates a standard procedure regarding
undecided patients in the Bone Marrow Transplant system, for
the multidisciplinary team
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USE OF A MULTIDISCIPLINARY COLLABORATIVE GROUP TO DEVEL-
OP PAIN PATHWAYS SPECIFIC FOR BMT PATIENTS
Causton, C.; Johnston, P.; DelaCruz, B.; Gaudreaux, J.; Donato, M.;
Neumann,, J.; Gray, M.; McDonald, R.; Rios, R.; Hicks, K. MD
Anderson Cancer Center, Houston, TX
JCAHO has developed a standard of care for control of pain
that all hospitals seeking accreditation are required to meet.
Pain assessment has been called the fifth vital sign and as such
needs to be assessed with every shift and with each clinic visit.
Pain control becomes an ethical issue where there are differ-
ences in the goal of care and lack of knowledge related to
appropriate medications,equaianalgesic conversion, type of
pain or addictive disorders. We in cancer care need to be lead-
ing the way in innovative means of looking at the recognition
and treatment of pain. As part of a hospital pain initiative col-
laborative study into issues of pain, a multidisciplinary group
was set up in the BMT section. This group consists of both
inpatient and outpatient personnel in order to give a broader
view of the issue of pain in Blood and Marrow Transplant
patients and to assure continuity of care in all settings. It is
made up of personnel involved in caring for our patients
including physicians, nurses, APN, PA, social worker, dietician,
physical therapist, and case manager. After discussing types of
pain in our patient population, we narrowed it down to two
main problem areas which we felt were the most common types
of pain, neuropathic pain and mucositis. We then divided into
two subgroups to focus more closely on each type of pain.
Experts in each of these fields were invited to share their expe-
riences and expertise with the groups. We also did extensive lit-
erature research to look at treatment plans. The goal of all this
is to develop specific pathways for both types of pain which we
would then use as standard practice of care, including treat-
ment options, education and data collection to ensure the best
treatment of pain for BMT patients.
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CORD BLOOD PROVIDES ALTERNATE OUTLET AS STEM CELL
SOURCE FOR ADULT TRANSPLANTS
De La Cruz, B.; Rivera, Z.R.; Neumann, J.; De Lima, M. MD
Anderson Cancer Center, Houston, TX
Historically, cord blood transplants were performed in children
due to the number of stem cells present. Evidence has shown the
percentage of using cord blood stem cells as a source for transplan-
tation has increased from 1995 through 2000 with adults. Actual
collecting of the cord blood is uncomplicated and noninvasive.
Upon delivery of the baby, the umbilical cord is clamped, blood is
withdrawn, and frozen for future use. The cells are simply thawed
when preparing for cord transplant producing approximately 25-
100cc. Experience has shown patients who have received cord
blood transplants may have severe reactions during infusion of the
cells or shortly thereafter possibly related to increased DMSO or
increased hemolysis, hypertensive crisis, and confusion. In addi-
tion to documented monitoring guidelines used for standard bone
marrow and peripheral blood stem cell transplants, the patient are
cardiac monitored for close observation. Potential side effects
could include circulatory overload, pulmonary complications,
allergic reactions, and possibly hemolysis. Advantages of cord
blood transplants are that the collection and immediate banking of
cells is without risk to mother or baby, decreased risk of transmit-
ting infectious diseases, immunologically naïve, lowered inci-
dences of GVHD, and cells have greater proliferation potential .
Some disadvantages are low cell doses(50-200cc), logistics of col-
lection, potential contamination, delayed processing, FDA regula-
tion pending, storage costs, revenues with transplant, and relative-
ly low fraction of units used. With cord blood being a rich source
of hemopoetic stem cells, it can potentially address unmet need of
ﬁnding adequate donor for all patients. To overcome the problem
of lower cell counts in adults, multiple cords are being infused at
our center. This will initially result in mixed chimerism with one
cell line eventually dominating. Results of our research program
with cord blood as well as nursing implications will be presented.
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CREATING A SAFE AND COST EFFECTIVE COMPREHENSIVE OUTPA-
TIENT BLOOD & BONE MARROW TRANSPLANTATION PROGRAM
De Leon, C.M.; Ng, J.; Wallace, S.; Neumann, J.; Champlin, R. Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX
Over the past four decades, major advancement has been made
in the science of blood and bone marrow transplantation. Innova-
tive treatments (i.e. nonmyeloblative chemotherapy) and
improved recognition and management of treatment side effects
have made it possible to consider performing the entire transplant
procedure in the outpatient setting. The benefits of performing
outpatient transplants are multi-factorial. The reduced costs of
outpatient transplants allow for managed care contracts that are
feasible. Patients are able to maintain a higher quality of life since
they are able to stay in an environment that they are comfortable
with as opposed to being tethered to an inpatient unit. The
decreased risk of nosocomial infections is another benefit that
could be extrapolated from performing transplants in the outpa-
tient setting. Although there are obvious beneﬁts to performing
outpatient transplants, caution should still be exercised. The treat-
ment regimen and its toxicity proﬁle should be considered when
choosing protocols appropriate for outpatient transplants. Ensur-
ing that patients have a responsible and vested caregiver is also
paramount for the success of an outpatient transplant program. In
collaboration with physicians, advanced practice nurses, pharma-
cists, and outpatient staff, an outpatient autologous transplant pro-
gram was developed at our center. Over a year ago, we began per-
forming transplants in an outpatient clinic staffed by an advanced
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practice nurse and pharmacist in concert with the physicians.
Information on the clinic development, daily functioning, as well
as patient education material will be presented. Data on the num-
ber of patients, complications/toxicities, and hospital admission
rates will also be presented.
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THE NECESSITY OF MUGA SCANS TO DETECT RISKS FOR CARDIAC
TOXICITY IN PATIENTS CONSIDERED FOR BONE MARROW
TRANSPLANTATION
Garcia, I.; Rodriguez, T.E.; Davies, S.; Havey, C.; Klingemann, H.G.
Rush-Presbyterian St. Luke’s Medical Center, Chicago, IL
The majority of patients who undergo bone marrow transplan-
tation (BMT) have received chemotherapy regimens that are
known to be cardiotoxic. Radionuclide ventriculography or multi-
ple gated acquisition scan (MUGA) is useful in determining car-
diac functional status. MUGA scans are a routine part of the pre-
transplant evaluation and are required by insurance companies to
determine if patients can safely tolerate the BMT preparative regi-
men. We reviewed our experience with MUGA scans in 75 con-
secutive patients who underwent BMT to examine the need for
routine pre-treatment MUGA scan. The medical records of these
patients were reviewed to identify prior therapy with cardiotoxic
regimens, pre-existing cardiac conditions, cardiac risk factors
(CRFs) as determined by the American Heart Association (AHA),
MUGA scan results, and cardiac toxicity (CTox) post-transplanta-
tion utilizing the National Cancer Institute cardiac toxicity crite-
ria. Results: Forty-ﬁve of 75 (58.6%) patients had received prior
chemotherapy with cardiotoxic agents. Seven of 75 (9.3%) had
pre-existing cardiac conditions. Twenty of 75 (26.6%) had ≥ 4
CRFs deﬁned as ≥ 65 years of age, sex, family history, race, tobac-
co history, hypercholesterolemia, hypertension, obesity, and dia-
betes mellitus. Three of 75(4%) had ejection fractions (EFs) less
than 50%. All 75 patients completed the preparative regimen.
Three of 75 (4%) patients experienced Grade I CTox, and one
patient (1.4%) developed Grade III CTox. The four patients who
developed CTox, had EFs ≥ 50%, did not have pre-existing car-
diac conditions, and had ≤ 3 CRFs. The patient who developed
Grade III CTox did so after undergoing two allogeneic trans-
plants within 6 months. The patients who had EFs < 50% did not
experience CTox. Conclusion: These results demonstrate that
pre-transplant MUGA scans will screen out very few, if any
patients at risk for treatment related cardiac toxicity. In this cost-
conscious medical environment, guidelines recommending routine
use of MUGA scans should be reconsidered.
182
BUILDING A DREAM TEAM: MEASURING NURSE MANAGERS’ PER-
SONAL TRAITS AND LEADERSHIP CHARACTERISTICS TO IMPROVE
ORGANIZATIONAL OUTCOMES ON AN INPATIENT BLOOD AND MAR-
ROW TRANSPLANT UNIT
Johnston, P.A. University of Texas M. D. Anderson Cancer Center,
Houston, TX
The registered nurse occupies a pivotal role in the effective
operation of an inpatient blood and marrow transplant unit. This
role requires considerable strength and maturity in mastering the
demands of practice in an evolving work environment. Experts
contend that leadership acumen as required by today’s nurse man-
ager, is distinguished from management proﬁciency primarily by
the unique interpersonal characteristics of the leader, which pro-
duce professional commitment among staff. Satisfaction and
retention among the nursing work group have been correlated
with leadership style. An initiative to evaluate nurse manager lead-
ership style and it’s relationship to staff nurse turnover was under-
taken at a large comprehensive cancer center. The Management
Council, one of the institutional shared-governance nursing bod-
ies consisting of directors, nurse mangers and staff from across the
facility, coordinated this effort. A questionnaire was developed
resulting from an extensive literature search on the measurement
of staff perception of nurse manager interpersonal style leadership
characteristics. The results of this initiative will be reviewed. Sub-
sequent to the survey, nurse managers developed action plans to
establish personal and leadership growth objectives. Ultimately,
improving interpersonal competency and leadership expertise can
foster effective working relationships and can contribute to a
shared unit identity, which supports organizational cohesion.
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A REVIEW OF NON-MYELOABLATIVE UNRELATED UMBILICAL CORD
BLOOD TRANSPLANTS IN ADULTS
Lassiter, M. Duke University Health System, Durham, NC
Participating in Phase I research protocols is a challenging area
of oncology nursing practice. Patients are generally heavily pre-
treated for their disease, have poor performance status, and or no
other treatment options. Over the past 18 months, we have treat-
ed 7 adult patients on a Phase I clinical trial using a non-myeloab-
lative preparative regimen and unrelated umbilical cord blood.
This poster will review toxicities, incidence of graft versus host
disease, infection and engraftment rates. The use of a non-mye-
loablative preparative regimen allows patients to experience mini-
mal side effects and inpatient days during the ﬁrst 100 days fol-
lowing transplant. Developing strategies to manage the more
common post 100 day complications while still allowing the
patient the best quality of life provides a unique challenge to the
entire health care team. Although challenging, assisting with the
implementation of Phase I protocols provides a unique opportuni-
ty to help current and future oncology patients.
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FINDERS, KEEPERS: IMPROVING RECRUITMENT AND RETENTION
EFFORTS ON AN INPATIENT BLOOD AND MARROW TRANSPLANT UNIT
Davis, L.; Johnston, P.A.; Causton, C.; Blackburn, R.; Jewell, J. Uni-
versity of Texas M. D. Anderson Cancer Center, Houston, TX
Nursing’s tight labor market within the global healthcare work-
force shortage mandates institutional vigilance about recruitment
and retention efforts. With crippling nurse vacancies across the
nation, escalation in nurse turnover rates, and a widely anticipated
increase in nurse retirement, retention issues have evolved in
importance to rival cost and quality imperatives. Model long-term
solutions to counter turnover are the focus of innovation. The
Inpatient Blood and Marrow Transplant Unit at our comprehen-
sive cancer center has successfully reduced registered nurse
turnover by nearly 10%. In collaborative with the shared-gover-
nance council structure, a unit-based taskforce developed strate-
gies to address this issue. Staff nurses, the nurse manager, assistant
nurse managers, clinical nurse specialists, the clinical instructor
and clinical administrative director created mechanisms to mini-
mize the three highest drivers of staff turnover: 1.) strengthen new
hire education and support; 2.) reconﬁgure scheduling and work-
load intensity and address compensation; and 3.) evaluate staff sat-
isfaction with nurse manager performance. These interventions
will be discussed in detail. Designing a successful recruitment and
retention plan and sustaining these improvements efforts can facil-
itate change in stafﬁng patterns which support longevity in spe-
cialty clinical practice.
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PRACTICAL APPROACHES USED BY THE ADVANCED PRACTICE
NURSE IN FACILITATING CONTINUITY OF CARE IN A COMMUNITY-
BASED PRACTICE
Metoyer, L.J.; Champlin, R.E. MD Anderson, Houston, TX
Transitioning from a large comprehensive cancer center to a
community-based practice is an overwhelming, challenging event
for both the patient and receiving institution. Even with the best
of planning, there can be unexpected obstacles in this critical tran-
sition, which can lead to fear and anxiety for the health care prac-
titioners, patient and the patient’s family. However, the advanced
practice nurse (APN) can make a signiﬁcant impact in the conti-
nuity of care across the continuum by developing an effective, col-
laborative follow-up program. This program should intricately
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combine the support and resources of two distinct institutions
with the purpose of ensuring a successful outcome and improve-
ment in the patient’s quality of life. This abstract will explore the
experience of the APN in facilitating the return and transition of a
specialized patient group to the community from a comprehensive
cancer facility. There are several key roles that the APN must
assume during the transition, including facilitator, educator, col-
laborator, and communicator. As facilitator, the APN is to prepare
the patient and his or her family for the transition. As educator,
the APN can teach the patient about pertinent signs and symp-
toms, the disease process and management, pertinent laboratory
results, both one on one with patient and with the local physi-
cian’s ofﬁce. As collaborator, the APN can serve as a coordinator
between both practices while maintaining a primary focus on the
patient. As communicator, the APN can develop an effective
means of communicating pertinent clinical information and labo-
ratory test results and aid in symptom management and interven-
tions for expected and unexpected complications. Finally, but
most importantly, tools such as protocols and pathways must be
developed that will allow for sufficient, consistent follow-up for
the patient as well as provide clear guidelines and interventions for
potential problems.
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BUSULFAN IN BMT-BACK TO THE FUTURE
Meyers, A.L.; Siler, J.; Andersson, B. University of Texas-MD Ander-
son Cancer Center, Houston, TX
Busulfan is an alkylating agent used for the treatment of
hematologic diseases. It was first used in 1953 for palliative
purposes in a low dose oral route. Unfortunately, pulmonary
fibrosis and occassional irreversible myelosuppression were
noted. Beginning in 1974 oral Busulfan was trialed in a pre-
transplant regiment for autologous and allogeneic transplants
in advanced disease. Again there were several serious complica-
tions associated with this study such as increased risk for devel-
oping veno-occlusive disease(VOD)and severe nausea and vom-
iting shortly after dose administration which altered the
pharmacokinetics. This showed us that oral high dose Busulfan
carried a poential high risk for the patient to have lethal dose
toxicities. Other challenges with the drug included grand mal
seizures, potential overdosing or subtherapeutic dosing due to
the patients nutrtional status, a higher rate of graft verus host
disease (GVHD),and a higher reoccurrence of malignancy post
transplant. It was not until 1996 that our comprehensive cancer
center started using IV Busulfan in a phase two study, every six
hours, four times a day. Over the years the research of pharma-
cokinetics of IV busulfan has progressed to IV once a day. The
results have shown us that with convenient once a day dosing
there is less VOD, less nausea and vomiting, less GVHD, and a
higher remission post transplant. Finally, BMT nurses play an
invaluable role in the success of clinical trial studies. It’s
important with Busulfan for nurses to be proactive with educa-
tion, have vigilance in monitoring for side effects, and timely
lab draws which are crucial for the pharmacokinetics, which
will enhance the future success of IV Busulfan. Also of great
importance is the monitoring of daily labs for liver function,
which may influence the delivery of other liver toxic drugs.
Our presentation will show how Busulfan has advanced over
the years.
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A COMPETENCY-BASED ORIENTATION PATHWAY FOR NOVICE
NURSES IN BLOOD AND MARROW TRANSPLANTATION
Mishaw, K. University of Texas M.D. Anderson Cancer Center, Hous-
ton, TX
Today’s nursing shortage is evidenced by fewer nurses entering
the workforce, acute nursing shortages in certain geographic
areas, and a shortage of nurses prepared to meet specialty patient
needs in a changing health care environment. This is clearly evi-
dent in the blood and marrow transplant unit at MDACC, which
processes approximately 500 transplants/year. It is a challenge to
recruit nurses with cancer experience, much less, with a back-
ground in this specialty. Although nurses like the challenging
environment including the latest treatment and technology, many
verbalize that the unit is too daunting in terms of the learning
curve. In response to this concern, this BMT unit reﬁned its cur-
rent orientation program utilizing a orientation pathway; This
pathway includes the hospital orientation, the BMT unit orienta-
tion, and additional clinical experiences to provide the “big pic-
ture” of the transplant process. Orientation content is standard-
ized and sequenced with identified time frames for learning.
Variances from the pathway are easily identiﬁed such that action
plans can be devised to meet the learners needs. Competency
based orientation tools are utilized with the pathway to reflect
mastery of the content. Additional clinical experiences to enhance
the learning of this challenging treatment modality are included
(Clinical time in the ambulatory BMT clinics, pheresis unit and
cGVHD clinic). Weekly post-clinical seminars with case scenarios
are conducted to enhance critical thinking, assessment, data col-
lection, priority setting, and decision-making skills in these novice
nurses. This approach to orientation, empowers the nurse with
the knowledge to provide competent care for this patient popula-
tion and may serve as a model for future “residency” programs for
nurses in BMT arena. This presentation will detail the pathway,
the tools utilized, cost analysis and the outcomes.
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EMERGING THERAPIES IN THE TREATMENT OF AGVHD
Mishaw, K.; Ippolitti, C.; Champlin, R. University of Texas M.D.
Anderson Cancer Center, Houston, TX
As we continue to increase the number of MUD and mis-
matched allograft transplants done each year, the successful man-
agement of GVHD is critical to a positive outcome of the trans-
plant. In this presentation, the results of the current management
of acute GVHD at a major comprehensive transplant center per-
forming over 500 transplants per year will be presented. Current
update in pathophysiology of GVHD will be reviewed including
role of nonimmunologic events i.e. tissue damage from condition-
ing regimen, cytokine storm. The prophylactic standard of care
will be reviewed along with the MDACC standard of care. The
ﬁrst line treatment of aGVHD with steroids as well as the second
line treatment of ATG will be reviewed with nursing considera-
tion. Potential roles for emerging therapies (steroid sparing) to be
presented will include: Daclizumab, Infliximab, ATG, Thy-
moglobulin, and Pentostatin The pharmakinetics, mechanism of
action, side effect profile, dosing, administration concerns, and
nursing management of each agent will be presented.
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CONTINUITY OF CARE: MEETING THE CHALLENGES IN HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Mitchell, S.A. University of Maryland, Greenebaum Cancer Center,
Baltimore, MD
Achieving continuity of care is of paramount importance to
quality care for patients undergoing hematopoietic stem cell trans-
plantation (HSCT). The experience of HSCT involves an ongo-
ing experience with the health care system that extends over a
long period of time, and usually includes a number of transitions
between health care settings and health care providers. Typically,
these transitions also involve shifts in the roles and responsibilities
of care providers, patients and families, and whenever such
changes occur, the possibility for discontinuity exists. A team of
health care professionals and an array of services is required to
meet the complex, multidimensional needs of these patients.
However, achieving integration between all of these services, care-
givers, and care settings, although crucial for the well being of the
patient, is a challenge. This paper provides an integrated review of
the conceptual and clinical challenges of continuity of care for this
patient population. After reviewing the various philosophies and
deﬁnitions, and discussing the evolution of the concept, the barri-
ers to continuity of care are briefly examined. The paper then
describes the seven key components necessary for achieving conti-
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nuity of care, and outlines individual and program-centered strate-
gies to achieve continuity of care for patients undergoing HSCT.
These seven key components can serve as benchmarks for clini-
cians, program administrators, and researchers seeking to opera-
tionalize and evaluate continuity of care in this patient population.
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EVALUATING THE IMPACT OF ETHICS ROUNDS ON BMT NURSES’
ROLES AS CAREGIVER AND PATIENT ADVOCATE
Neumann, J.L.; Flamm, A.; Pentz, R.; Blackburn, R.; Smith, M. Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX
As direct caregivers and patient advocates, nurses are responsi-
ble for supporting patients in their physical, psychological and
emotional responses to medical diagnoses. At our major compre-
hensive center, characteristics of hematology patients present
numerous challenges to fulfilling this duty. The majority of
patients are enrolled in research protocols, which involve aggres-
sive treatments with severe side effects. This is especially true in
treatments including blood and marrow transplantation. In the
last two years, MDACC has conducted over 117 ethics consults,
30% have involved hematology patients. Nurses were infrequent
user of ethics consults, but often verbalized discomfort in contin-
uing treatments that may be considered futile. Ethics rounds were
initially started 2 years ago in order to increase nurses’ knowledge
of ethics principles, provide an avenue for discussion and empow-
er nurses to participate in the clinical decision-making process.
To evaluate the effectiveness of ethics rounds a survey was creat-
ed and administered to nurses who had attended. Preliminary
results of the survey indicate that 99% of nurses who have attend-
ed rounds have reported that this has helped them in their prac-
tice; 92% report better understanding of ethical principles; 80%
report increase knowledge of advanced directives; 88% reported
they are more prepared to talk to MD’s and patients about difﬁ-
cult issues. Individuals that the nurses identiﬁed as sharing their
ethical concerns with were principally colleagues, charge nurse,
advanced practice nurse and physicians. Fear of conﬂict was iden-
tified as the major barrier to requesting a consult. Additional
results of the survey are being examined and a formal study is
being submitted. The feasibility of expanding ethic rounds to
other units of the hospital is being explored. The ultimate goal of
supporting nurses in their role of patient advocates, thereby
improving the quality of care to our cancer patients, will also be
examined.
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CORD BLOOD PROVIDES ALTERNATE OUTLET AS STEM CELL
SOURCE FOR ADULT TRANSPLANTS
Rivera, Z.R.; De La Cruz, B.; Neumann, J.; De Lima, M. MD
Anderson Cancer Center, Houston, TX
Historically, cord blood transplants were performed in children
due to the number of stem cells present. Evidence has shown the
percentage of using cord blood stem cells as a source for trans-
plantation has increased from 1995 through 2000 with adults.
Actual collecting of the cord blood is uncomplicated and noninva-
sive. Upon delivery of the baby, the umbilical cord is clamped,
blood is withdrawn, and frozen for future use. The cells are simply
thawed when preparing for cord transplant producing approxi-
mately 25-100cc. Experience has shown patients who have
received cord blood transplants may have severe reactions during
infusion of the cells or shortly thereafter possibly related to
increased DMSO or increased hemolysis, hypertensive crisis, and
confusion. In addition to documented monitoring guidelines used
for standard bone marrow and peripheral blood stem cell trans-
plants, the patient are cardiac monitored for close observation.
Potential side effects could include circulatory overload, pul-
monary complications, allergic reactions, and possibly hemolysis.
Advantages of cord blood transplants are that the collection and
immediate banking of cells is without risk to mother or baby,
decreased risk of transmitting infectious diseases, immunologically
naïve, lowered incidences of GVHD, and cells have greater prolif-
eration potential . Some disadvantages are low cell doses(50-
200cc), logistics of collection, potential contamination, delayed
processing, FDA regulation pending, storage costs, revenues with
transplant, and relatively low fraction of units used. With cord
blood being a rich source of hemopoetic stem cells, it can poten-
tially address unmet need of finding adequate donor for all
patients. To overcome the problem of lower cell counts in adults,
multiple cords are being infused at our center. This will initially
result in mixed chimerism with one cell line eventually dominat-
ing. Results of our research program with cord blood as well as
nursing implications will be presented.
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HUMAN HERPESVIRUS-6 (HHV-6) IN THE PEDIATRIC PATIENT
AFTER STEM CELL TRANSPLANTATION
Runge, S.M. Duke University, Durham, NC
In 1986, the human herpesvirus-6 (HHV-6) was isolated from
patients with lymphoproliferative disorders and from patients
with acquired immunodeficiency syndrome (AIDS). More than
90% of the general population is seropositive for HHV-6, mak-
ing it one of the most widespread of the human herpesviruses.
HHV-6 seroconversion peaks by 2 years of age and may be
asymptomatic or can present as a febrile illness with a resulting
exanthem subitum (roseola infantum). Following the primary
infection, the virus remains latent within the body but can be
reactivated causing a secondary infection during states of
immunosuppression as occurs in stem cell transplantation. This
opportunistic pathogen is an important cause of morbidity and
mortality in pediatric patients receiving stem cell transplants.
Reactivation of the virus typically occurs within the first 30
days after transplant. An association between HHV-6 and fever
and skin rash resembling graft-versus-host disease (GVHD),
interstitial pneumonitis, encephalitis, and bone marrow sup-
pression has been documented. The Pediatric Stem Cell Trans-
plant Program at Duke University has had five documented
cases of HHV-6 encephalitis. Treatment with antiviral therapy
has been effective. The purpose of this abstract is to: 1)
Describe the etiology, pathophysiology and incidence of sec-
ondary HHV-6 infection in pediatric stem cell transplant
patients. 2) Educate health care providers about presenting
signs and symptoms of HHV-6 infection. 3) Discuss treatments
and the long-term outcomes for pediatric stem cell transplant
patients following HHV-6 infection. 4) Describe nursing
strategies to care for immunocompromised patients experienc-
ing a reactivation of HHV-6. HHV-6 provides little health risk
to immunocompetent children; however, in the stem cell trans-
plant population, the virus can cause severe and fatal complica-
tions. Early recognition of the presenting signs and symptoms
by the health care team will allow for faster diagnosis and treat-
ment implementation in an effort to reduce morbidity and
mortality.
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CLINIC OBSERVATION OF BASIC FIBROBLAST GROWTH FACTOR TO
ORAL ULCER IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
PATIENTS
Su, R.; Ruan, X. Great Wall Hospital, Beijing, China
In this study, 34 patients with Hematopoietic Stem Cell trans-
plantation were randomly divided into cured with basic ﬁbroblast
growth factor(b-FGF) group and control group when they went
into LAFR. Two groups were measured with degree of oral ulcer,
VAS of pain, oral ulcer lasting time and happened time and oral
PH. The oral ulcer of the two groups was cured at discharge from
LAFR, but the degree of oral ulcer and VAS of pain in the cured
group was much lower than those of control group(P<0.005), and
oral ulcer lasting time was shorter than that of control
group(P<0.05). But there was not different in oral ulcer happened
time and oral PH between two groups. The result indicated that
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using b-FGF was beneﬁt to oral ulcer in Hematopoietic Stem Cell
transplantation.
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A QUALITY-CONTROLLED, REAL-TIME, SINGLE-ENTRY, BMT CLINI-
CAL DATA SYSTEM WITH MULTIPLE OUTPUTS CAPABILITY
Gardner, D.H.; Pena, O.B.; Salzman, D.E.; Shackelford, M.A.;
Vaughan, W.P. Bone Marrow Transplantation Program, University of
Alabama Birmingham, Birmingham, AL
BMT clinical systems have multiple data reporting needs, including
quality assurance and research, registry and managed care reporting.
We have developed a data system that provides live, secure, single-
entry input of the data required for all these purposes to a relational
Oracle database. Sophisticated Seagate CrystalReports software gen-
erates these and additional outputs on-line or on paper, including
clinical documents such as problems lists in JCHO required and daily
progress note formats. The data entry cycle includes weekly updates
on 13 NCI CTC scores, active problems, and history. As a single-
entry system, it has reduced the need for re-recording the same infor-
mation via several means/media—thus reducing redundancy of effort
by professional, data, and clerical staff. It has also improved the accu-
racy and timeliness of data collection, transmission, and sharing. This
database contains separate tables for pre-transplant, transplant, post-
relapse, post-DLI, and re-transplant episodes, to more accurately
document BMT Program outcomes in support of research productiv-
ity, IRB (and outside entity) reporting and clinical quality assurance.
Development is towards increasingly user-friendly and intuitive input
mechanisms via secure Oracle Portal on our database, and in consid-
eration of HIPAA requirements. Authorized, authenticated users
enjoy encrypted-link ﬁeld-level input and information review using
standard Web browsers from any location—within or without the
Medical Center. This could include special access/reporting from
external entities, such as referring physicians, national registries, and
appropriate others. Thus, this data management system has been
developed beyond standard internal, external, and research reporting
to enhance patient care on a working BMT Unit, while simplifying
and enhancing data recording and transmission throughout all ofﬁces,
levels and phases of Program operation to simultaneous, multiple
users. These efﬁciencies will increase many-fold with the improve-
ment of ease of use and expansion to new users now in development.
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ANALYSIS OF QUALITY OF ENGRAFTMENT IN STEM CELL TRANS-
PLANT PATIENTS UTILIZING A MULTIPLE-USER CENTRALIZED
DATABASE
Wang, Y.; Rodriguez, T. Rush Presbyterian St. Luke’s Medical Center,
Chicago, IL
We analyzed the quality of engraftment of 159 consecutive
patients, who underwent stem cell transplantation in our institu-
tion, utilizing a Multiple-User Centralized Bone Marrow Trans-
plant (BMT) Database. The distribution of patients by transplant
type is: 59 allogeneic matched sibling (ASCT), 81 autologous
(AuSCT), 15 matched unrelated donor (MUD), 2 cord blood and
2 syngeneic. Quality of engraftment was evaluated based on the
speed of recovery of absolute neutrophil count (ANC), red blood
cell count (RBC) and platelet count (PLT). Late engraftment (LE)
was defined as an ANC>500/mm3 not achieved by day+14 post
autografting or day+21 post allografting, and/or PLT>20 TH/UL
not achieved by day+30 or platelet transfusion dependent after
day+30, RBC transfusion dependent after day+30. Kaplan-Meier
method, Wilcoxon and Log-rank statistics in univariate analyses
were used. RESULTS: Thirty-three patients had LE (AuSCT=21,
ASCT=8). With a median follow up of 11 months, survival was
analyzed. LE had no negative impact on overall survival (OS) or
disease free survival (DFS) in AuSCT recipients. However, ASCT
recipients with LE had a lower OS that was statistically signiﬁcant
by Wilcoxon (P=0.0194) and Log-rank (P=0.0370) analyses com-
pared to ASCT recipients with adequate engraftment. Peripheral
stem cell transplant (PSCT) patients had faster engraftment of
ANC (P=0.0048), PLT (P=0.0187) and RBC (P=0.0087) than
bone marrow transplantation patients. ASCT patients had faster
engraftment of ANC (P=0.0076) and PLT (P=0.007) than AuSCT
and MUD patients. Furthermore, non-myeloablative ASCT
recipients had an earlier recovery of ANC (P=0.0451), PLT
(P=0.0061), and RBC (P=0.0391) than myeloablative transplant
recipients. Age and sex did not affect engraftment significantly.
CONCLUSIONS: A Multiple-User Centralized BMT Database
is a helpful tool for the analysis of quality of engraftment in
patients after stem cell transplantation. PSCT and ASCT are
independent predictors of adequate engraftment. Quality of
engraftment after ASCT but not after AuSCT seems to predict
survival.
